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Introduction {#sec005}
============

For many years, gastric cancer (GC) has been one of the most common cancer in the world and one of the leading causes of death worldwide.\[[@pone.0163719.ref001]\] Some methods, such as computed tomography, magnetic resonance imaging and endoscopy ultrasonography, can predict the preoperative tumor stage to some extent, however, it is not precise. Furthermore, these examinations are prohibitively expensive. In the future, we expect that an ideal marker will be developed to predict the prognosis of gastric cancer. In fact, there are no ideal predictors that can be reliably used in the clinic. Therefore, we aim to discover a reliable predictive marker, and our clinicians and researchers have been making efforts to identify this type of bio-marker. Recently, we may have had some success, as an increasing number of studies have shown that a systemic inflammatory response has a relationship with the development and progression of cancer \[[@pone.0163719.ref002]--[@pone.0163719.ref004]\]. Inflammation-based variables, such as the PLT count, the NLR, the PLR, etc., may be predictive markers for the prognosis of gastric cancers \[[@pone.0163719.ref005]--[@pone.0163719.ref010]\]. Among these markers, the PLR may be the most controversial \[[@pone.0163719.ref011],[@pone.0163719.ref012]\]. Recently many studies have been performed to assess its prognostic value in gastric cancer \[[@pone.0163719.ref005],[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref013]--[@pone.0163719.ref016]\]. According to their results, the prognostic role of the PLR remains inconsistent. So we conducted this meta-analysis to evaluate the prognostic role of the PLR in gastric cancer

Materials and Methods {#sec006}
=====================

Literature search {#sec007}
-----------------

We conducted a systematic literature search in PubMed, Embase and the Cochrane Library. The search for relevant studies was performed using the following terms: ("platelet-lymphocyte ratio" or "platelet-to-lymphocyte ratio" or "platelet lymphocyte ratio" or PLR) and ("gastric cancer" or "gastric adenocarcinoma" or "gastric carcinoma" or "stomach tumor" or "stomach neoplasms"). A MeSH/Emtree search for "stomach neoplasms" was also performed. (Appendix 1) Three databases were searched from inception to July 20, 2016. We scanned the reference lists of all studies that had been identified in order to search for other potentially eligible studies. All articles were assessed independently by two authors according to the eligibility criteria that we had designed. Articles were independently categorized based on their title and abstract. When articles could not be categorized based on this information, the full-text was retrieved and reviewed. Any disagreements or questions were resolved by consulting another author. According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@pone.0163719.ref017]\], the selection process of the articles is shown in [Fig 1](#pone.0163719.g001){ref-type="fig"}.

![Literature screening flow chart and results.\
doi:[10.1371/journal.pmed1000097](http://dx.doi.org/10.1371/journal.pmed1000097).](pone.0163719.g001){#pone.0163719.g001}

Inclusion and exclusion criteria {#sec008}
--------------------------------

Studies were included if they met the following criteria: (a) all patients must have been diagnosed with GC by a pathological examination; (b) there was available data to be investigated (for example the number of patients and the presence or absence of lymph node metastasis, the depths of tumor invasion or stage of gastric cancer, or HR and 95%CI on the OS which was provided by the original article or could be calculated from Kaplan-Meier cumulative survival curves and the number of patients\[[@pone.0163719.ref018]\]); and (c) the patients had blood samples all obtained before treatment; (d) any study designs and without restriction in sample size. Studies were excluded based on the following criteria: (a) those consisting of letters, conference abstracts, review articles, and posters (b) those lacking required outcomes data that could not be calculated from the article data; (c) studies referring to any treatment (including operative or/and chemoradiotherapy) prior to their blood draw; and (d) those lacking human research.

Data collection and assessment of methodological quality {#sec009}
--------------------------------------------------------

Two investigators independently evaluated and extracted the data. Any disagreements or questions were resolved by consulting another co-author. The following information was recorded from each study: first author, year of publication, country, study design, the type of gastric cancer, age, the cut-off value of PLR, the number of patients with or without lymph node metastasis, the depths of tumor invasion or different stage of gastric cancer, or HR and 95% CI on the OS that was provided by the original articles or could be calculated from Kaplan-Meier cumulative survival curves and the number of patients. The same investigator assessed the quality of each study using the Newcastle--Ottawa Scale (NOS) \[[@pone.0163719.ref019]\]. Each study with NOS scores ≥6 was regarded as a high quality study, and studies with NOS scores \<6 were regarded as a low quality study.

Statistical analysis {#sec010}
--------------------

For this meta-analysis, we measured HR or ORs with 95% confidence for pooled outcomes with a random effects model \[[@pone.0163719.ref020]\].I^2^ statistic was used to evaluate the heterogeneity of pooled outcomes. If I^2^ \>50%, it suggested significant heterogeneity among included studies. To explore other sources of heterogeneity among studies of the OS outcome in this meta-analysis, subgroup analyses of OS according to geographic, research styles and cutoff values were conducted; To validate the credibility of the OS outcome in this meta-analysis, an sensitivity analysis was also performed by removing one study at a time using the ''metaninf" STATA command. Because all pooled outcomes included less than ten trials, publication bias was not evaluated. All statistical analyses were performed using RevMan (version 5.2, Cochrane Library) and Stata 12.0 (StataCorp LP).

Results {#sec011}
=======

Our search strategy found 85 records. After we removed the duplications by computer and scanned each article by hand, 49 articles were left. We then screened the 49 articles, and 22 studies were identified to be eligible potentially. Ultimately, after reading all 22 studies, 8 full-text articles with a combined 4513 gastric cancer patients were included \[[@pone.0163719.ref005],[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref013]--[@pone.0163719.ref016],[@pone.0163719.ref021]\]. We summarized the characteristics of the included studies in [Table 1](#pone.0163719.t001){ref-type="table"}. All 8 studies were cohort studies (6 retrospective and 2 prospective studies) published between 2010 and 2016.

10.1371/journal.pone.0163719.t001

###### Characteristics of included studies in meta-analysis.

![](pone.0163719.t001){#pone.0163719.t001g}

  First author    Year   Country   Study design    Patients(n)   Age (years)   Treatment   Cut-off value   Study period   NOS score
  --------------- ------ --------- --------------- ------------- ------------- ----------- --------------- -------------- -----------
  Aliustaoglu M   2010   Turkey    retrospective   168           60.1±12.1     surgery     \>160           2004--2008     6
  Deng Q          2015   china     retrospective   389           NA            surgery     ≥132            2007--2009     7
  Gunaldi M       2015   Turkey    retrospective   245           59.6±11.8     surgery     ≥160            NA             7
  Jiang N         2014   China     prospective     377           64±11.7       surgery     ≥184            2005--2007     8
  Kim E Y         2015   Korea     prospective     1986          58.2±11.7     surgery     \>126           2000--2009     8
  Pang W-y        2016   China     retrospective   392           63(medain)    surgery     \>155.67        NA             7
  Sun K-y         2015   China     retrospective   632           57(medain)    surgery     \> 140          1998--2008     7
  Wang D-s        2012   China     retrospective   324           NA            surgery     150/300         2006--2009     7

NA: No available, NOS: Newcastle-Ottawa Scale.

In comparison to normal PLR,the high PLR had a higher risk of lymph node metastasis with OR of 1.50 (95% Cl:1.24--1.82; I2 = 17%) ([Fig 2A](#pone.0163719.g002){ref-type="fig"}) \[[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref014],[@pone.0163719.ref015],[@pone.0163719.ref020]\]; Coincidentally, the high PLR had a higher risk of serosal invasion (T3 +T4) with OR of 1.99 (95% Cl: 1.60--2.46; I2 = 28%) ([Fig 2B](#pone.0163719.g002){ref-type="fig"}) \[[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref014],[@pone.0163719.ref015],[@pone.0163719.ref020]\]; The high PLR also increased the advanced stage (III +IV) risk with OR 1.99 (95% Cl: 1.60--2.46; I2 = 28%) ([Fig 2C](#pone.0163719.g002){ref-type="fig"}) \[[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref014],[@pone.0163719.ref015],[@pone.0163719.ref020]\]. An high PLR is not a reliable predictor for OS, however, with an HR of 0.99, it may be a reliable predictor (95%CI: 0.9--1.1; P heterogeneity = 0.34) ([Fig 3A](#pone.0163719.g003){ref-type="fig"}) \[[@pone.0163719.ref005],[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref013]--[@pone.0163719.ref016]\]. Subgroup analyses of OS according to geographic, research styles and cutoff values were conducted, and these results excluded the potential source of heterogeneity among including studies to some extent ([Table 2](#pone.0163719.t002){ref-type="table"}); we also performed sensitivity analyses for the OS by removing one study at a time to determine whether an individual study influenced the results; there was no significant influence by any single study ([Fig 3B](#pone.0163719.g003){ref-type="fig"}). All above results suggested that our results had no obvious heterogeneity between the included studies. All studies with NOS scores ≥6 were regarded as high quality studies.

![**Forrest plots of included studies evaluating ORs of PLR for lymph node involvement (A), serosal invasion (B), and AJCC staging (C) in gastric cancer.** OR = odds ratio, AJCC = American Joint Committee On Cancer, PLR = platelet-lymphocyte ratio, CI = confidence interval, M-H = Mantel-Haenszel.](pone.0163719.g002){#pone.0163719.g002}

![**Forrest plots (A), sensitivity analyses (B) of included studies evaluating HR of PLR for OS.** OS = overall survival, CI = confidence interval, IV = inverse variance, SE = standard error.](pone.0163719.g003){#pone.0163719.g003}

10.1371/journal.pone.0163719.t002

###### Subgroup analyses results.

![](pone.0163719.t002){#pone.0163719.t002g}

  OS   Variables       No.Trial   No.Patient   Model    HR\[95%Cl\]           I^2^   Test for subgroup differences I^2^)
  ---- --------------- ---------- ------------ -------- --------------------- ------ -------------------------------------
       Total           7          4121         Random   0.99 \[0.90, 1.10\]   12%    No applicable
       Country                                                                       31.10%
       China           4          1722         Random   1.05 \[0.92, 1.19\]   9%     
       Turkey          2          413          Random   0.86 \[0.71, 1.04\]   0%     
       Korea           1          1986         NA       1.03 \[0.81, 1.33\]   NA     
       Cut-off                                                                       49%
       \<160           3          3007         Random   1.10 \[0.95, 1.26\]   0%     
       ≥160            3          790          Random   0.91 \[0.78, 1.07\]   0%     
       150/300         1          324          NA       0.87 \[0.66, 1.13\]   NA     
       Research type                                                                 0%
       Prospective     2          2363         Random   1.05 \[0.86, 1.27\]   0%     
       Retrospective   5          1758         Random   0.94 \[0.84, 1.06\]   37%    

I^2^ statistic was used to evaluate the heterogeneity of pooled outcomes.OS = overall survival, HR = hazard ratio, CI = Confidence interval, NA = No applicable

Discussion {#sec012}
==========

Many predictive methods have attempted to show an association with the prognosis of various cancers, but these methods may be expensive and unreliable for the prediction of the cancer prognoses. Recently, it was noted that inflammation and the interaction between various inflammatory cells and the extra-cellular matrix plays a crucial role in the tumor micro-environment of tumorigenesis, progression and metastasis \[[@pone.0163719.ref002]--[@pone.0163719.ref004],[@pone.0163719.ref022],[@pone.0163719.ref023]\]. The peripheral blood count can partly reflect the inflammatory response and is routinely conducted with no need for additional effort in patients. In addition, it is convenient and inexpensive \[[@pone.0163719.ref011]\]. There are two potential interacting mechanisms between inflammation and cancer. First, by generation of reactive oxygen species and proinflammatory cytokines, inflammation may slowly initiate oncogenesis \[[@pone.0163719.ref003],[@pone.0163719.ref022]\]. Recently, Qian BZ and Pollard JW demonstrated that at the early stage of the neoplastic progression, inflammation definitely promoted benign neoplasms to cancers \[[@pone.0163719.ref023]\]. On the other hand, cancer could generate inflammation and that inflammation could then promote low grade malignancies to transition to states of heightened malignancy by genetic evolution \[[@pone.0163719.ref004],[@pone.0163719.ref024]\]. Based on these studies, research has attempted to identify the prognostic role of various inflammation-based factors including the PLR, NLR, and the platelet count in cancer patients.

Among various inflammation-based factors, the role of the PLR is the most controversial. Nieswandt B proved that platelets are capable of protecting tumor cells from cytolysis and can promote metastasis. Surface shielding by integrin αIIbβ3 (glycoprotein IIb/IIIa) bridging seems to be the main mechanism of this protection\[[@pone.0163719.ref025]\], and platelets can also secrete inflammatory proteins such as IL-6, TNF-α, et al, which have also been linked to tumor cell metastases \[[@pone.0163719.ref026],[@pone.0163719.ref027]\]. In addition, by the release of secretory factors that promote growth factors, chemokines, proangiogenic regulatory proteins, proteolytic enzymes and microparticles within the microenvironment, activated platelets promote tumor cell growth and invasion \[[@pone.0163719.ref028]\]. Moreover, Bambace NM demonstrated that platelets might stimulate tumor generation and promote metastasis by creating angiogenic factors, for example platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) \[[@pone.0163719.ref029]\]. In addition, a high platelet number would lead to relative lymphocytopenia, and the patient with cancer would have a hypoimmune response that is linked to lymphocyte-mediated antitumor activity at the cellular level.

Based on these above researches, systemic inflammatory parameters, such as the PLR (platelet-lymphocyte ratio), the NLR (neutrophil-lymphocyte ratio) and the platelet count (PLT), have been found to be associated with the prognosis of gastric cancer; however, these results, especially those relating to the PLR, remain inconsistent \[[@pone.0163719.ref005],[@pone.0163719.ref006],[@pone.0163719.ref011],[@pone.0163719.ref013]--[@pone.0163719.ref016]\]. Although a meta-analysis was conducted and showed that PLR was a negative predictor for gastric cancer in the subgroup, several hundred patients from only 3 articles were included, the 95% confidence intervals were wide, and the conclusion was not realistic with significant heterogeneity \[[@pone.0163719.ref012]\]. Thus, the prognostic value of the PLR remains inconclusive in gastric cancer. So we aimed to evaluate the prognostic role of the PLR in gastric cancer by conducting and presenting the findings of this meta-analysis. There are two highlights in this analysis. Firstly, blood counts were all derived from the patients' pretreatment, so it eliminated the influence of the treatment, particularly the chemoradiotherapy influence that can lead to granulocytopenia. Secondly, this is the first meta-analysis about the prognostic role of the PLR in gastric cancer.

This analysis demonstrated that a high PLR is linked to a higher risk of lymph node metastasis, and the high PLR also increased the serosal invasion (T3 +T4) risk and the advanced stage (III +IV) risk in patients with gastric cancer. Although the specific mechanism is still incompletely understood, our results are in accordance with other studies that found that the PLR was a negative prognostic factor for various cancers, such as pancreatic ductal adenocarcinoma, hepatocellular carcinoma and colorectal cancer \[[@pone.0163719.ref030]--[@pone.0163719.ref034]\]. In this research we found that the PLR could not act as a significant biomarker in the OS of gastric cancer. And subgroup analyses for OS revealed that no differences could distinctly be found in China, Korea or Turkey. Given the various cut off values of the PLR in the included studies, the effects of these different cut off values on the prognostic value of the PLR was evaluated. As well we found that patients with a high PLR did not suffer a worse OS compared to those with a low PLR, regardless of different cut off values. Moreover we also eliminated the effect of different research types on the prognostic value of the PLR. To further improve the pooled result, we used the leave-one-out sensitivity analyses of OS by removing one study at a time to assess if an individual study influenced the results. The result pattern was not obviously impacted by any single study. These results might strengthen the possibility that the PLR cannot be a reliable biomarker in predicting the OS of gastric cancer patients. Some studies also indicated that the PLR is not an independent predictor of cancer OS in gastric cancer. \[[@pone.0163719.ref005],[@pone.0163719.ref008],[@pone.0163719.ref035]\]

There were several limitations in this study. Firstly, this analysis was constrained to only 8 studies and only those published in English, so publication bias could not be excluded. Secondly, there are no randomized controlled trials (RCTs), however, our conclusion is stable with low heterogeneity. Thirdly, many studies in which the local and advanced cancer groups showed an altered PLR after treatment should have been included in our research; however, considering the lack of important clinical parameters, the clinical significance of the PLR could not be further validated. The greatest limitation was the diverse values of the PLR cutoff used in different studies within this meta-analysis. Despite this, the prognostic value of the PLR was not affected, as the majority of the subgroup analysis of the PLR cutoff base on OS did not substantially change the result. Furthermore, a sensitivity analysis was stable from the pooled estimates, which intensified the conclusions. Another limitation is that the HR is heavily dependent on one study \[[@pone.0163719.ref011]\]. However, if we remove the study, the results remain steady in the analysis. In the future, studies with a larger sample size and more cancer types are needed for more reliable results.

In conclusion, a high PLR was correlated with a higher risk of lymph node metastasis, serosal invasion and advanced stage (III +IV) risk in gastric cancer; However the PLR may not be a significant biomarker in the OS of gastric cancer. We suggest that the PLR could be used before treatment to provide reliable information for patients with gastric cancer.
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